KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

Imipenem/cilastatin/relebactam dosing regimen justification using exposure-efficacy analyses in participants with hospital-acquired bacterial pneumonia or ventilator-associated bacterial pneumonia in the RESTORE-IMI 2 phase 3 study.

Munjal Patel, Garrett Nieddu, C Andrew DeRyke, Katherine Young, Luke Francis Chen, Amanda Paschke, Matthew L Rizk, Ferdous Gheyas

Antimicrob Agents Chemother 70(3) e0131325

PMID41586496
PMCIDPMC12959156
DOI10.1128/aac.01313-25
发表日期2026-01-26
入排依据:未发现恶性肿瘤人群证据。
已检查 4 张 PubMed Figure,均未识别为 KM 图:Fig 1:AI 判定为 flow diagram;Fig 2:AI 判定为 other;Fig 3:AI 判定为 other;Fig 4:AI 判定为 other。
摘要

摘要

An exposure-efficacy analysis of the phase 3 RESTORE-IMI 2 study (NCT02493764) evaluated the relationship between plasma exposure of imipenem and relebactam and key efficacy endpoints (primary: 28-day all-cause mortality [ACM]; secondary: clinical response at early follow-up [EFU; 7-14 days after the end of treatment]) in adult participants with hospital-acquired bacterial pneumonia (HABP) or ventilator-associated bacterial pneumonia (VABP) who received imipenem/cilastatin/relebactam 500/500/250 mg (IMI/REL). Participants from the IMI/REL treatment group in the microbiological-modified intent-to-treat population who had pharmacokinetic (PK) data and relevant baseline pathogen susceptibility data available were included (N = 211). Previously developed population PK models were used to derive steady-state imipenem and relebactam exposures. Exposures were analyzed against the primary and secondary endpoints overall and by the most common key pathogens identified during RESTORE-IMI 2 (Pseudomonas aeruginosa, Klebsiella pneumoniae, Acinetobacter calcoaceticus-baumannii complex, and Escherichia coli). Most participants (82.0%; n = 168/205) achieved the imipenem exposure target, and 83.9% (n = 177/211) achieved the relebactam exposure target. ACM was 16.1% overall; 11% among participants who met the imipenem exposure target, and 18% among those who met the relebactam exposure target. At EFU, 62.1% of participants experienced a favorable clinical response. Efficacy was similar across the overall exposure range and by key pathogens. There were no apparent trends in ACM rates by imipenem or relebactam exposure distributions overall or by individual key pathogens, suggesting an exposure-efficacy plateau. These results further support the recommended and currently approved IMI/REL 500/500/250 mg dosing regimen for patients with HABP/VABP.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(4,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Fig 1Fig 1 Participant population for the exposure–efficacy analysis. MITT, modified intent-to-treat; mMITT, microbiological modified intent-to-treat; PK, pharmacokinetic. Note that some participants had polymicrobial infections, and, thus, the number of participants with any key pathogen infection is less than if summing the number with each individual pathogen.
非 KM Figure
Fig 2Fig 2 All-cause mortality by achievement of the relebactam exposure target ( f AUC 0–24 /MIC ≥ 8) in the exposure–efficacy analysis population ( n = 211). AUC, area under the concentration-time curve; f AUC 0–24 /MIC, free area under the concentration-time curve from 0 to 24 h normalized to MIC; MIC, minimum inhibitory concentration.
非 KM Figure
Fig 3Fig 3 Clinical response by relebactam exposure. AUC, area under the concentration-time curve; f AUC 0–24 /MIC, free area under the concentration-time curve from 0 to 24 h normalized to MIC; MIC, minimum inhibitory concentration.
非 KM Figure
Fig 4Fig 4 All-cause mortality by achievement of target imipenem exposure ( f T > MIC for at least 40% of the dosing interval) in the exposure–efficacy analysis population ( n = 205). % f T > MIC, percentage of time free drug concentration exceeded the minimum inhibitory concentration.
非 KM Figure